FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – USA – 02/2024”.
The Monitor is a month-to-month printed overview of enterprise capital traits within the US Healthcare & Life Sciences sector.
As of the top of February 2024 we establish the next present VC traits in the USA:
- Whole Healthcare & Life Sciences funding has reached EUR 5,224m
- Biotech acquired 58% of the full funding quantity (EUR 3,040m) with oncology being the main indication (30%)
- In February Areteia Therapeutics secures the very best transaction quantity with EUR 392m, adopted by Freenome with EUR 235m and BioAge with EUR 178m
- Premji Make investments (United States) is essentially the most energetic investor (by deal quantity), adopted by Novo Holdings (Denmark) and Sands Capital (United States)
To entry the total report, please click on right here.
By Mathias Klozenbücher und Johannes Hyperlink.